Glaxosmithkline and yale university establish drug discovery collaboration to design potential new class of medicines Full Text
GlaxoSmithKline,

GlaxoSmithKline plc and Yale University have established a drug discovery research collaboration to design a potential new class of medicines that degrade disease–causing proteins. The collaboration combines GSK's expertise in medicinal chemistry with Yale's pioneering work on proteolysis targeting chimeric molecules or PROTACs. PROTAC technology guides disease–causing proteins to a cell's garbage disposal where they can be destroyed. Mutant or higher–than normal amounts of these proteins typically drive disease progression in areas such as oncology, inflammation and infections; yet many cannot be tackled by traditional ways of making drugs.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Pharma News

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Pharma News Articles

1 FDA approves Afrezza to treat diabetes Full Text FDA Press Announcements, June 30, 2014    Free full text

2 Duke team brings life-saving function to ketchup packets Duke University Health & Medicine News, July 3, 2014

3 FDA releases first-ever purple book for biosimilar characterization Full Text BioPharm International, October 3, 2014    Free full text

4 FDA releases guidance on OTC pediatric drug products Full Text BioPharm International, October 20, 2014    Free full text

5 Four ways to improve pharmacovigilance processes with automation Full Text Applied Clinical Trials, October 6, 2014    Free full text

6 Sanofi and Regeneron announce positive phase 2 top-line dupilumab results in patients with chronic sinusitis with nasal polyps Full Text Sanofi, October 3, 2014    Free full text

7 Bristol-Myers Squibb announces multiple regulatory milestones for Opdivo (nivolumab) in the U.S. and European Union Full Text Bristol Myers-Squibb, October 3, 2014    Free full text

8 Factors affecting the uptake of new medicines: A systematic literature review Full Text BMC Health Services Research, October 24, 2014    Free full text    Evidence Based Medicine    Review Article

9 Sarepta therapeutics announces publication of Ebola and Marburg phase I clinical study results in antimicrobial agents and chemotherapy Full Text Sarepta Therapeutics, October 17, 2014    Free full text

10 Crowdfunding: the open-source option against capital crunch Pharmaceutical Executive Magazine, October 17, 2014

11 Newly-approved empagliflozin for obese patients with type 2 diabetes First Report Managed Care, October 10, 2014

12 Boston scientific receives FDA and CE mark approval for new CoverEdge surgical leads for the precision Spectraâ„¢ Spinal Cord Stimulator (SCS) system Full Text Boston Scientific, October 24, 2014    Free full text

13 Efficacy of honey in reduction of post tonsillectomy pain, randomized clinical trial International Journal of Pediatric Otorhinolaryngology , October 24, 2014    Clinical Article
Exclusive Author Commentary

14 10 Reasons to make the Baltic States A location for your next clinical trial Full Text Applied Clinical Trials, October 17, 2014    Free full text

15 MedImmune and Cancer Research UK establish joint CRUK-MEDI Alliance Laboratory to develop new biologic cancer medicines Full Text AstraZeneca, October 3, 2014    Free full text

16 With an eye on growth, Agfa healthcare expands North American executive team Imaging Economics, October 3, 2014

17 Sanofi Pasteurs dengue vaccine candidate successfully completes final landmark phase III clinical efficacy study in Latin America Full Text Sanofi, October 10, 2014    Free full text

18 New report details players and pipelines in the biosimilar space Full Text BioPharm International, October 3, 2014    Free full text

19 Teva announces initiation of new drug application and positive results from second human abuse liability study for CEP-33237 (hydrocodone bitartrate) extended-release tablets Full Text Teva Pharmaceutical Industries, October 10, 2014    Free full text

20 Existing FDA pathways have potential to ensure early access to, and appropriate use of, specialty drugs Health Affairs, October 10, 2014    Review Article

Indexed Journals in Pharma News: U.S.Pharmacist, FDA Drug Alerts, Pharmiwebmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register
Upcoming Clinical Trials UPCOMING Clinical Trials

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close